Cannapharmarx, Inc.

CannaPharmaRx, Inc. is a U.S.-listed company that has shifted from its earlier corporate history to focus on cannabis cultivation and medical cannabis product sales, primarily through operations in Canada. The company recommissioned a 55,000 square foot indoor facility in Cremona, Alberta, and now produces and sells medical cannabis and craft products. Its recent revenue growth has been driven by expanded product offerings, improved distribution, and new retail partner relationships. The business remains early-stage and capital constrained, with operations still scaling and significant dependence on financing and related-party support.

−153,1 %

−817,2 %

+66,1 %

0.04

0.01

— Cannapharmarx, Inc.
%
Medical cannabis products85% Cultivated cannabis flower and related medical-use products sold into domestic and export channels.
Craft cannabis products10% Higher-specification batches marketed at premium pricing based on potency and quality.
Wholesale distribution5% Bulk product sales to retail partners and related-party distributors that move inventory into end markets.

The company sells cannabis products to retail partners and distributors that place product into medical cannabis...

  • Retail cannabis partnersprimary

    Retail partners buy medical cannabis inventory for resale, helping the company expand market penetration and distribution reach.

  • International distributorssecondary

    Distributors in markets such as Israel and Europe buy batches for local medical cannabis channels and market development.

  • Related-party commercial buyerssecondary

    Affiliated buyers have purchased product and appear to support early commercialization and market access.

  • Premium batch buyerssecondary

    Customers seeking higher-THC, higher-priced batches buy for quality and potency differentiation.

Operationally, the company is centered in Alberta, Canada, where it runs its indoor cultivation facility and maintains...

  • •Canada is the operating base and main production location
  • •Cremona, Alberta facility is the core cultivation asset
  • •Calgary, Alberta is the principal executive office
  • •Sales references include Germany, Israel, Canada, and Portugal
  • •International market access affects pricing and commercialization

The company’s strategy is to scale its indoor cannabis farm, increase utilization of the Cremona facility, and expand...

01
Increase facility utilizationmedium-term

Higher utilization should spread fixed cultivation costs over more output and improve commercial scale.

02
Expand distribution and retail partnershipsshort-term

Broader channel access is needed to convert production into recurring sales and reduce reliance on a small set of buyers.

03
Secure financing and liquidityshort-term

The company needs external capital to fund operations, working capital, and expansion while it remains cash constrained.

The most immediate risk is going concern and liquidity risk, as the company reports minimal cash, a large working...

critical

Going concern and liquidity shortfall

The company states it lacks adequate working capital and depends on raising additional capital to meet obligations and continue operations.

Scope
Corporate liquidity and operating continuity
Materiality
high
high

Inventory impairment and price compression

Management recorded large inventory write-downs because market prices fell and some inventory failed potency thresholds or became less marketable.

Scope
Gross margin and inventory valuation
Materiality
high
high

Cannabis regulatory and licensing risk

Cultivation and sales depend on Health Canada and other jurisdiction-specific standards that can change product recoverability and market access.

Scope
Operations and sales channels
Materiality
high
medium

Related-party dependence

Sales, leases, loans, and security arrangements involve affiliates and insiders, increasing dependence on non-arm's-length support.

Scope
Financing, commercial terms, governance
Materiality
medium
Inventory impairment and net realizable value
Directly reduces gross margin and can signal product quality or demand issues
Revenue recognition on cannabis sales
Creates volatility in reported revenue and comparability across quarters
Related-party lease and royalty arrangements
Can materially affect cost of goods sold, liabilities, and financing disclosures
Going concern assessment
Affects investor assessment of asset recoverability and financing assumptions

Cannaisseur Group Inc.

TCRG · Medicinal Chemicals & Botanical Products

Target Group Inc.

CBDY · Medicinal Chemicals & Botanical Products

Cannabis Bioscience International Holdings, Inc.

CBIH · Services-Commercial Physical & Biological Research

HYDROFARM HOLDINGS GROUP, INC.

HYFM · Wholesale-Miscellaneous Nondurable Goods

Raphael Pharmaceutical Inc.

RAPH · Medicinal Chemicals & Botanical Products

Canopy Growth Corp

CGC · Medicinal Chemicals & Botanical Products

: 11/08/2026